TrialNeurology(R) neuroimmunology & neuroinflammation2021

Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.

Romain Marignier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.